Meeting News Coverage

Novel ocular biometer enhances precision of IOL power calculation

ISTANBUL — A novel ocular biometer that combines a Purkinje imaging method and an OCT device has the potential to produce highly accurate and reproducible measurements for IOL power calculation, according to one speaker.

Michael Mrochen

“It might be a promising solution for both normal and challenging cases, such as post-LASIK eyes or implantation of toric IOLs,” Michael Mrochen, PhD, said at the winter meeting of the European Society of Cataract and Refractive Surgeons.

After preliminary experiments in model eyes, the new biometer (ClearSight Innovations) was tested in a group of 34 subjects, including 10 normal eyes, 16 eyes with varying degrees of cataract and 14 pseudophakic eyes. All eyes were first tested with standard-of-care technology (WaveLight OB820, Alcon Surgical).

“Comparison with the standard-of-care device showed high correlation. In addition, our novel device has the capability of measuring additional elements, such as the posterior cornea and the geometry of the anterior and posterior crystalline lens, which are sensitive parameters for refractive prediction,” Mrochen said.

Disclosure: Mrochen reports he is a shareholder of ClearSight Innovations.

ISTANBUL — A novel ocular biometer that combines a Purkinje imaging method and an OCT device has the potential to produce highly accurate and reproducible measurements for IOL power calculation, according to one speaker.

Michael Mrochen

“It might be a promising solution for both normal and challenging cases, such as post-LASIK eyes or implantation of toric IOLs,” Michael Mrochen, PhD, said at the winter meeting of the European Society of Cataract and Refractive Surgeons.

After preliminary experiments in model eyes, the new biometer (ClearSight Innovations) was tested in a group of 34 subjects, including 10 normal eyes, 16 eyes with varying degrees of cataract and 14 pseudophakic eyes. All eyes were first tested with standard-of-care technology (WaveLight OB820, Alcon Surgical).

“Comparison with the standard-of-care device showed high correlation. In addition, our novel device has the capability of measuring additional elements, such as the posterior cornea and the geometry of the anterior and posterior crystalline lens, which are sensitive parameters for refractive prediction,” Mrochen said.

Disclosure: Mrochen reports he is a shareholder of ClearSight Innovations.

    See more from ESCRS Winter Meeting